From Aspergillus Patents (Class 435/225)
  • Patent number: 9399769
    Abstract: The present invention relates to isolated polypeptides having carboxypeptidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 26, 2016
    Assignee: Novozymes, Inc.
    Inventor: Michael Rey
  • Patent number: 8815571
    Abstract: Novel fiber processing methods and the products obtained therefrom are disclosed. Methods may include thermochemical and/or enzymatic hydrolysis of fiber feedstocks including distillers' dried grains, distillers' dried grains with solubles, soyhull, miscanthus and switchgrass. Enzymatic hydrolysis includes hydrolysis with cellulase, hemicellulase, and protease.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: August 26, 2014
    Assignee: Archer Daniels Midland Co.
    Inventors: Charles A. Abbas, Wu-Li Bao
  • Publication number: 20140205587
    Abstract: Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Matthew John Siegel
  • Patent number: 8765442
    Abstract: The invention relates to a process for production of an enzyme product having a plurality of enzyme activities obtained by fermentation of an Aspergillus strain.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: July 1, 2014
    Assignee: DuPont Nutrition Biosciences ApS
    Inventor: Mette Zacho Grønfeldt
  • Patent number: 8741626
    Abstract: The present invention relates to a mutant strain of Aspergillus sojae with an enhanced protease activity and a preparation method of a natural taste enhancer using the same. More specifically, the present invention relates to the mutant strain of Aspergillus sojae with an enhanced protease activity is obtained by selecting a strain with high protease activity and treating it with N-methyl-N?-Nitroso-N-nitrosoguanidine (NTG) and inducing a mutation through irradiating, and a preparation method of a natural taste enhancer using protein hydrolysate obtained by hydrolyzing the protein sources with their cultures.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 3, 2014
    Assignee: CJ Cheiljedang Corporation
    Inventors: Hyun Chi, Seong-Jun Cho
  • Patent number: 8735563
    Abstract: The present invention relates to isolated polynucleotides having promoter activity the juse of the isolated polynucleotides for the procuction of a polypeptide. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing a desired polypeptide using the polypeptide having promoter activity.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: May 27, 2014
    Assignee: Novozymes A/S
    Inventors: Hiroshi Teramoto, Hiroaki Udagawa
  • Patent number: 8580557
    Abstract: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein hydrolysate of the present invention contains free amino acids and peptides, such as in vivo indigestible peptides including Xaa-Pro and Xaa-Pro-Pro, obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, and has ACE inhibitory activity or hypotensive effect.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: November 12, 2013
    Assignee: Calpis Co., Ltd.
    Inventors: Naoyuki Yamamoto, Seiichi Mizuno, Takanobu Gotou, Keiichi Matsuura, Tadashi Shinoda, Hideo Nishimura
  • Publication number: 20130156884
    Abstract: A food supplement comprises at least one protease enzyme selected from (i) CAS #9001-92-7, IUB 3.4.23.18 protease from Aspergillus; (ii) CAS #9001-92-7, IUB 3.4.21.7 protease from Bacillus; (iii) CAS #9001-61-0, IUB 3.4.11.1 protease from Aspergillus; (iv) CAS #9074-07-1, IUB 3.4.21.63 protease from Aspergillus; (v) CAS #9073-78-3, IUB 3.4.24.27 protease from Aspergillus; (vi) CAS #9025-49-4, IUB 3.4.23.18 protease from Aspergillus; and (vii) combinations thereof. The food supplement may further comprise a protein, a stabilizer, a matrix modifier, a carrier, a preservative, a bulking agent, a dessicant, an emulsifier, an enzyme coating, or combinations thereof. Disclosed is a method of increasing protein absorption in the gastrointestinal system of a human being comprising the step of ingesting the food supplement as identified above.
    Type: Application
    Filed: December 19, 2011
    Publication date: June 20, 2013
    Applicant: TRIARCO INDUSTRIES
    Inventor: Mark L. Anderson
  • Publication number: 20130122545
    Abstract: The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: January 17, 2013
    Publication date: May 16, 2013
    Applicant: NOVOZYMES A/S
    Inventor: NOVOZYMES A/S
  • Publication number: 20130065810
    Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence of the mature Fe_RF6318 enzyme having an amino acid sequence of SEQ ID NO: 15. The serine protease is obtainable from Fusarium equiseti, more preferably from the deposited strain CBS 119568. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2521 comprising the nucleotide sequence SEQ ID NO:9 deposited in E. coli RF7664 under accession number DSM 22171 and plasmid pALK2529 comprising the full-length gene SEQ ID NO: 10 deposited in E. coli RF7800 under accession number DSM 22172. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Application
    Filed: April 28, 2010
    Publication date: March 14, 2013
    Applicant: AB Enzymes Oy
    Inventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo
  • Publication number: 20120276075
    Abstract: The present invention relates to a novel enzyme composition comprising a prolyl protease and tripeptidyl proteases having unique catalytic properties. The present invention further relates to methods for producing the enzyme composition as well as a pharmaceutical composition and a food supplement containing the enzyme composition and its use in the degradation of polypeptides.
    Type: Application
    Filed: December 20, 2010
    Publication date: November 1, 2012
    Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
    Inventors: Michel Monod, Eric Grouzmann
  • Patent number: 8198068
    Abstract: A method of forming localized variation of color density in the surface of a dyed cellulosic fabric with reducing back staining, with a composition comprising a cellulose having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 75% sequence identity with SEQ ID NO: 2 is provided. A method for biopolishing a cellulose-containing fabric by using the new endoglucanase is also provided.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: June 12, 2012
    Assignee: Novozymes A/S
    Inventors: Guifang Wu, Sarah Teter, Paul Harris, Weijian Lai
  • Publication number: 20120141628
    Abstract: The invention relates to a method for the prevention or reduction of haze in a beverage by the addition of an prolyl-specific endoprotease and to new beverages obtainable by the method according to the invention. It also relates to new endoproteases. Sequence information of a genomic DNA, cDNA as well as protein sequences.
    Type: Application
    Filed: January 13, 2012
    Publication date: June 7, 2012
    Applicant: DSM IP Assets B.V.
    Inventors: Michel LOPEZ, Luppo Edens
  • Patent number: 7998476
    Abstract: A method for treating various diseases, conditions and injuries with a protease preparation derived from Aspergillus orzyze and made using potato dextrin as the carbohydrate source is described. The method comprises orally administering the Aspergillus oryzae protease preparation on an empty stomach and in an amount greater than about 2,000,000 HUT per day. Additionally, a method for treating various diseases, conditions and injuries with a protease derived from Aspergillus oryzae made using potato dextrin as the carbohydrate source along with a nutritional supplement of vitamins and minerals is also described. The method comprises orally administering the Aspergillus oryzae protease preparation on an empty stomach in an amount of greater than 2,000,000 HUT per day and administering the dietary supplement of vitamins and minerals orally with food.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: August 16, 2011
    Assignee: Standard Biologics, Inc.
    Inventor: Joseph Cerceo
  • Patent number: 7897728
    Abstract: The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: March 1, 2011
    Assignee: Gelita AG
    Inventors: John M. Dolphin, Jason D. Russell
  • Publication number: 20110028375
    Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence the mature Fa_RF7182 enzyme having an amino acid sequence of SEQ ID NO: 18. The serine protease is obtainable from Fusarium acuminatum, more preferably from the deposited strain CBS 124084. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2530 comprising the nucleotide sequence SEQ ID NO:12 deposited in Escherichia coli RF7803 under accession number DSM 22208 and plasmid pALK2531 comprising the full-length gene SEQ ID NO: 13 deposited in E. coli RF7879 under accession number DSM 22209, as well as fungal hosts, such as Trichoderm. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Application
    Filed: April 28, 2010
    Publication date: February 3, 2011
    Applicant: AB Enzymes Oy
    Inventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo, George Szakacs
  • Publication number: 20110003729
    Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence of the mature Fe_RF6318 enzyme having an amino acid sequence of SEQ ID NO: 15. The serine protease is obtainable from Fusarium equiseti, more preferably from the deposited strain CBS 119568. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2521 comprising the nucleotide sequence SEQ ID NO:9 deposited in E. coli RF7664 under accession number DSM 22171 and plasmid pALK2529 comprising the full-length gene SEQ ID NO: 10 deposited in E. coli RF7800 under accession number DSM 22172. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Application
    Filed: April 28, 2010
    Publication date: January 6, 2011
    Applicant: AB Enzymes Oy
    Inventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo
  • Patent number: 7785824
    Abstract: Process for the preparation of a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP, wherein a substrate comprising casein or casein fragments is subjected to enzyme treatment wherein the enzyme is derived from Aspergillus, wherein the enzyme concentration is 2-10 wt. % based on casein and that the enzyme has a high proteolytic activity.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 31, 2010
    Assignee: Conopco Inc.
    Inventors: Monique Cecilia van der Burg-Koorevaar, René´ Bernardus Draaisma, Johannes Schalk
  • Patent number: 7608697
    Abstract: A method of enzymatically producing a protein hydrolysate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally a subtilisin or a metallo endoprotease, and other enzymes such as carboxypeptidases, is used to produce a protein hydrolysate enriched in peptide fragments having a carboxy terminal proline residue. Such protein hydrolysates may be used as such or to reduce bitterness in foods nutritionally supplemented by protein hydrolysates, as well as to produce hydrolysate containing foodstuffs having low antigenicity.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: October 27, 2009
    Assignee: DSM IP Assets B.V.
    Inventors: Luppo Edens, Robertus Antonius Mijndert Van Der Hoeven, Veronique Delest
  • Publication number: 20090181007
    Abstract: A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in combination, at least one proteolytic enzyme, at least one growth factor and at least one from a sugar, an amino acid, a vitamin factor, a vitamin, a nucleotide and a nucleoside, in a physiologically acceptable carrier or diluent. A method of differentiating stem cells in cells having a chondrocytic phenotype, the cells obtained by the method and their uses, for example in human or animal cell therapy, for example by CBMP (Cellular Based Medicinal products) are also described.
    Type: Application
    Filed: April 12, 2007
    Publication date: July 16, 2009
    Inventors: Luisa Gennero, Antonio Ponzetto, Enrico De Vivo, Luciano Contu, Emanuella Morra, Chiara Cesano, Giovanni Cavallo, Giuseppe Cicero, Gian Piero Pescarmona, Tetyana Denysenko, Maria Augusta Roos, Maurizio Sara
  • Patent number: 7323327
    Abstract: The invention relates to newly identified gene sequences that encode novel proteases obtainable from Aspergillus niger. The invention features the full length gene sequence of the novel genes, their cDNA sequences as well as the full-length functional protein and fragments thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with DNA according to the invention and cells wherein a protease according to the invention is genetically modified to enhance or reduce its activity and/or level of expression.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: January 29, 2008
    Assignee: DSM IP Assets B.V.
    Inventors: Luppo Edens, Albertus Van Dijk, Philipp Krubasik, Kaj Albermann, Alexander Stock, Erik Kimpel, Sabine Klugbauer, Christian Wagner, Andreas Fritz, Wilk Von Gustedt, Oliver Heinrich, Dieter Maier, Fabio Spreafico, Ulrike Folkers, Sylvia Hopper, Wolfram Kemmner, Pamela Tan, Josephine Stiebler, Richard Albang
  • Patent number: 7297512
    Abstract: From fish egg skin produced by utilization of roe grains of various fish, constituent proteins thereof are enzymatically degraded to obtain peptides and amino acids, of which effective utilization is achieved. The invention provides a method for producing amino acids and peptides (useful as nutrient enhancers for foods) from fish egg skins which comprises treating cold water-washed fish egg skins with ozonized water at room temperature or below, subsequently, degrading the resultant product with a proteolytic enzyme produced by Bacillus subtilis, or further treating with a proteolytic enzyme produced by Aspergillus oryzae, to degrade myogenic fiber proteins (contractile proteins: myosins) in the fish egg skin, and then concentrating/drying the degraded solution.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: November 20, 2007
    Assignee: Fuji Bio Technology Institute Co., Ltd.
    Inventor: Kunihiko Kodaka
  • Patent number: 7255888
    Abstract: The present invention discloses a method for producing foods and/or beverage having improved taste and/or flavour, comprising reacting a microbial aminopeptidase on a protein material optionally under the co-existence of a protease, wherein said aminopeptidase has the properties of: (a) having an activity of catalyzing the reaction of specifically releasing a glutamic acid and an aspartic acid from the N-terminal of a peptide and/or a protein; (b) having 50% or more activity at pH6.0-9.0 as compared with the activity at the optimum pH; (c) having 40% or more activity after heating at 25-60° C., pH7.5 for 30 minutes as compared with the activity of the non-heated enzyme; (d) having a molecular weight of about 40-60 kD as measured by SDS-PAGE and about 300-480 kD as measured by native-PAGE; (e) having a hydrolyzing activity of the aminopeptidase toward Glu-Glu dipeptide is 5 U/mg or more, preferably 10 U/mg or more.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: August 14, 2007
    Assignee: Ajinomoto Co., Inc.
    Inventors: Tomohiro Sakamoto, Nami Nakamura, Tomohiro Kodera, Noriki Nio, Noriaki Yamada, Hidehiko Wakabayashi
  • Patent number: 7087422
    Abstract: The object of the present invention is to provide Koji mold aminopeptidases capable of efficiently hydrolyzing persistent peptides and also genes encoding the aminopeptidases. The present invention provides Aspergillus nidulans aminopeptidase and nucleic acid molecules encoding it. In particular, the present invention provides a protein having an amino acid sequence represented by amino acid Nos. 1 to 519 in SEQ ID NO: 2, or a protein containing the substitution, deletion, insertion, addition or inversion of one or more amino acids in said sequence, and which protein has an activity of catalyzing the reaction for releasing an amino acid at an N-terminal of a peptide, and nucleic acid molecules encoding them.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: August 8, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Kyoko Koibuchi, Daiki Ninomiya, Mari Kojima, Yoichi Ueda, Jun-ichi Maruyama, Katsuhiko Kitamoto
  • Patent number: 6982163
    Abstract: A process for preparing beta-fructofuranosidase enzyme and a process for producing fructooligosaccharides, in which the preparation of the enzyme is obtained by cultivating the fungus Aspergillus niger, either wild or mutated, in a preferably semi-solid culture medium, in order to produce an extracellular enzyme, which is submitted to transfructosylation for producing fructooligosaccharides comprising sugars which are formed by one unit of sacrose and by two, three and four units of fructose.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: January 3, 2006
    Assignee: Usina Da Barra S/A-Acucar e Alcool
    Inventors: Yong Kun Park, Glaucia Maria Pastores
  • Patent number: 6951750
    Abstract: Provided are a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 and having prolidase activities, a prolidase gene coding for the protein, a prolidase gene comprising the nucleotide sequence as shown in SEQ ID NO: 1, recombinant DNA having the gene inserted into vector DNA, and a transformant or transductant comprising the recombinant DNA, and a method for producing prolidase using the transformant or transductant. The present invention can improve the prolidase through protein engineering. The present invention can be also used for improving microorganisms used in the production of enzymes for food processing and fermented foods.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: October 4, 2005
    Assignees: Kikkoman Corporation, Noda Institute for Scientific Research
    Inventors: Kotaro Ito, Takeharu Nakahara, Yasuji Koyama, Toshifumi Matsuda, Tadashi Takahashi, Kenichiro Matsushima, Genryou Umitsuki, Tsutomu Masuda
  • Patent number: 6899876
    Abstract: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: May 31, 2005
    Assignee: ProThera, Inc.
    Inventor: Devin B. Houston
  • Patent number: 6897049
    Abstract: The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein. Alternatively, T-cell epitopes are mutated to produce increased immunogenic reactions.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: May 24, 2005
    Assignee: Genencor International, Inc.
    Inventors: David A. Estell, Fiona A. Harding
  • Patent number: 6863918
    Abstract: An improved infant formula resulting in reduced constipation, abdominal discomfort and gastrointestinal problems, comprises at least one protein component having a phosphorus content of less than 0.75 g P/100 g protein, and at least one lipid component that can be easily digested by an infant. Preferably, it further comprises at least one prebiotic component, and at least one viscosity-improving component. The protein fraction of the formula is preferably a hydrolysate prepared by hydrolysing a protein starting material, especially a whey protein with a combination of at least one endo- and at least one exoproteinase.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: March 8, 2005
    Assignee: N.V. Nutricia
    Inventors: Jacob Geert Bindels, Antonie Van Baalen, Robert Johan Joseph Hageman, Peti Huybers, Liliane Marie-Rose Louisa Dominique Dumon
  • Patent number: 6846656
    Abstract: The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture, (iii) N-acetylmannosamine, and (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and recovering N-acetylneuraminic acid from the aqueous medium.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: January 25, 2005
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Satoshi Koizumi, Kazuhiko Tabata, Tetsuo Endo, Akio Ozaki
  • Patent number: 6821514
    Abstract: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: November 23, 2004
    Assignee: ProThera, Inc.
    Inventor: Devin B. Houston
  • Patent number: 6808708
    Abstract: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: October 26, 2004
    Assignee: ProThera, Inc.
    Inventor: Devin B. Houston
  • Patent number: 6770469
    Abstract: A novel enzyme which has an activity to release side chain carboxyl groups and ammonia from a protein by acting upon side chain amido groups in the protein. This invention relates to a method for the production of an enzyme, which comprises culturing in a medium a strain that belongs to a bacterium classified into Cytophagales or Actinomycetes and has the ability to produce an enzyme having a property to deamidate amido groups in protein, thereby effecting production of said enzyme, and subsequently collecting said enzyme from the culture mixture. It also relates to a method for the modification of protein making use of a novel enzyme which directly acts upon amido groups in protein as well as to an enzyme which has a property to deamidate amido groups in protein and a gene which encodes said enzyme.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: August 3, 2004
    Assignee: Amano Pharmaceutical Co., Ltd.
    Inventors: Shotaro Yamaguchi, Akira Matsuura
  • Patent number: 6447772
    Abstract: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: September 10, 2002
    Assignee: Klaire Laboratories, Inc.
    Inventor: Devin B. Houston
  • Patent number: 6379928
    Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: April 30, 2002
    Assignee: Genencor International, Inc.
    Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
  • Patent number: 6271013
    Abstract: Aminopeptidases originating from Aspergilli niger are disclosed, which can be produced in a fermentation broth or a liquid concentrate thereof substantially free of endoprotease. Such aminopeptidases may be advantageously employed in the food industry, e.g. in the preparation of bread doughs or cheese.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: August 7, 2001
    Assignee: DSM Patents and Trademarks
    Inventors: Laurent Chevalet, Jerome Souppe, Joel De Leseleuc, Jacky Brunet, Martinus J. M. Warmerdam
  • Patent number: 6251391
    Abstract: Compositions and methods are provided to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase. Preferrably the caseomorphinase is dipeptidyl peptidase IV and the gluteomorphinase is tyrosinase or phenylalaninase.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: June 26, 2001
    Assignee: Klaire Laboratories, Inc.
    Inventors: Randall Eugene Wilkinson, Devin B. Houston
  • Patent number: 6171817
    Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: January 9, 2001
    Assignee: Genencor International, Inc.
    Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
  • Patent number: 6130064
    Abstract: The invention provides a human SMN-like protein (HSLP) and polynucleotides which identify and encode HSLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSLP.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: October 10, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Y. Tom Tang, Neil C. Corley, Karl J. Guegler
  • Patent number: 6121025
    Abstract: The present invention relates to a process for producing optically active 3-quinuclidinol or derivatives, wherein a racemic 3-quinuclidinol ester represented by the general formula (I): ##STR1## wherein R represents a straight-chain or branched alkyl group, and (H.sup.+) represents that said ester may be in the form of a salt formed with a mineral acid or an organic acid, is reacted with a microorganism belonging to the genus Aspergillus, Rhizopus, Candida or Pseudomonas having the ability to asymmetrically hydrolyze said ester linkage, a culture of said microorganism, a treated material from said microorganism, an enzyme produced by said microorganism, or an enzyme derived from swine or cattle.According to the present invention, there is provided a process for easily producing optically active 3-quinuclidinol derivatives which are important synthetic intermediates for pharmaceutical preparations etc.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 19, 2000
    Assignee: Mitsubishi Rayon Co., Ltd.
    Inventors: Eiji Sato, Kanehiko Enomoto
  • Patent number: 6033867
    Abstract: The present invention relates to a fructosyl amino acid oxidase that is obtainable from a culture of a strain of the genus Aspergillus. This strain grows in a selective medium containing at least either of fructosyl lysine and fructosyl-N.sup..alpha. -Z-lysine and is capable of producing a fructosyl amino acid oxidase.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: March 7, 2000
    Assignee: Kyoto Daiichi Kagaku Co., Ltd.
    Inventors: Nobuo Kato, Yasuyoshi Sakai, Yoshiki Tani, Hiroshi Fukuya, Masayuki Yagi, Toshikatsu Sakai, Kaori Ishimaru, Satoshi Cyousa
  • Patent number: 6013452
    Abstract: The present invention relates to fungi, which do not produce proteases. The fungi of the invention are useful as hosts for the production of proteins susceptible of proteolytic degradation by the proteases usually produced, and the invention consequently encompasses processes for the production of proteins of interest in high yields by using the fungi of the invention. The invention also comprises methods for producing such fungi and DNA constructs to be used in these methods.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: January 11, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Tove Christensen, Jan Lehmbeck
  • Patent number: 5998190
    Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease activity in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO. 1 or 2.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: December 7, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
  • Patent number: 5989889
    Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having tripeptide aminopeptidase activity. The invention also relates; to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: November 23, 1999
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Michael Rey, Elizabeth Golightly
  • Patent number: 5939305
    Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: August 17, 1999
    Assignee: Novo Nordisk Biotech Inc
    Inventors: Debbie Sue Yaver, Sheryl Ann Thompson
  • Patent number: 5914259
    Abstract: Aminopeptidases originating from Aspergilli niger are disclosed, which can be produced in a fermentation broth or a liquid concentrate thereof substantially free of endoprotease. Such aminopeptidases may be advantageously employed in the food industry, e.g. in the preparation of bread doughs or cheese.
    Type: Grant
    Filed: January 30, 1997
    Date of Patent: June 22, 1999
    Assignee: Gist-brocades B.V.
    Inventors: Laurent Chevalet, Jerome Souppe, Joel De Leseleuc, Jacky Brunet, Martinus J.M. Warmerdam
  • Patent number: 5891669
    Abstract: The present invention relates to methods of producing a polypeptide, comprising: (a) introducing into a respiratory-defective mutant of a cell (i) one or more first nucleic acid sequences which complement the respiratory defect and (ii) a second nucleic acid sequence which encodes the polypeptide; (b) cultivating the cell containing the first and second nucleic acid sequences in a culture medium under aerobic conditions suitable for expression of the first and second nucleic acid sequences; and (c) isolating the polypeptide from the cultivation medium of the cell. The present invention also relates to methods for disrupting a gene in a respiratory-deficient mutant cell. The present invention further relates to respiratory-deficient mutant cells and methods for obtaining such mutant cells.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: April 6, 1999
    Assignees: Novo Nordisk A/S, Novoalle,, Novo Nordisk Biotech
    Inventors: Ejner Bech Jensen, Joel R. Cherry, Susan L. Elrod
  • Patent number: 5854050
    Abstract: A DNA construct comprising a DNA sequence encoding an enzyme exhibiting protease activity, which DNA sequence comprises the DNA sequence shown in SEQ ID No. 1 or 2 or an analog of any of these sequences being at least 80% homologous to the DNA sequence shown in SEQ ID No. 1 or 2. The proteases encoded by the DNA sequences have an acid pH optimum.
    Type: Grant
    Filed: February 1, 1996
    Date of Patent: December 29, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
  • Patent number: 5846802
    Abstract: The present invention concerns a novel DNA sequence coding for an Aspergillus serine protease of the subtilisin-type, an Aspergillus serine protease of the subtilisin-type per se and a method for the preparation thereof. The invention further concerns a novel Aspergillus mutant strain defective in a serine protease of the subtilisin-type, which is useful for the expression of heterologous protein, and a method for the preparation of such a mutant strain.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: December 8, 1998
    Inventors: Frank Buxton, Albert Hinnen, Jacob Visser
  • Patent number: 5843753
    Abstract: The present invention relates to a novel metalloprotease obtainable from a fungus having increased proteolytic activity. Additionally, the invention related to isolated nucleic acid fragments encoding said metalloprotease as well as vectors, DNA constructs, and recombinant host cells comprising said nucleic acid fragments.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 1, 1998
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Jeffrey R. Shuster, Mark Madden, Donna L. Moyer, Claus Fuglsang, Sven Branner